NewAmsterdam Pharma Company NV
Research NewAmsterdam Pharma Company NV (NAMS) on Bullrun: market cap USD 3.22B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNAMS
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.22B
- Financial periodQ2 2026
- RevenueUSD 3.70M
- Net income-USD 64.14M
- Free cash flow-USD 39.29M
Valuation Snapshot
latest market cap is USD 3.22B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 22.50M | -USD 203.00M | -USD 148.03M | n/a | -1.72 | USD 490.00M | USD 202.00K | USD 683.43M |
| FY2024 | USD 45.56M | -USD 242.00M | -USD 159.24M | n/a | -2.56 | USD 771.74M | USD 448.00K | USD 757.50M |
| FY2023 | USD 14.09M | -USD 177.00M | -USD 141.24M | n/a | -2.15 | USD 340.45M | USD 60.00K | USD 288.39M |
| FY2022 | USD 102.69M | -USD 22.63M | USD 10.44M | n/a | -1.19 | USD 467.73M | USD 126.00K | USD 430.07M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.22B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.01B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.78B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 919.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 889.00M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | n/a | 40.6 | n/a | n/a |
About NewAmsterdam Pharma Company NV
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NewAmsterdam Pharma Company NV's market cap?
NewAmsterdam Pharma Company NV's market capitalization is USD 3.22B.
What does NewAmsterdam Pharma Company NV do?
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.